- Home
- FNKO vs CRDF Comparison
FNKO vs CRDF Comparison
Compare FNKO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNKO
- CRDF
- Stock Information
- Founded
- FNKO 2017
- CRDF 1999
- Country
- FNKO United States
- CRDF United States
- Employees
- FNKO N/A
- CRDF N/A
- Industry
- FNKO Recreational Games/Products/Toys
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FNKO Consumer Discretionary
- CRDF Health Care
- Exchange
- FNKO Nasdaq
- CRDF Nasdaq
- Market Cap
- FNKO 170.7M
- CRDF 152.3M
- IPO Year
- FNKO 2017
- CRDF N/A
- Fundamental
- Price
- FNKO $3.03
- CRDF $2.25
- Analyst Decision
- FNKO Buy
- CRDF Strong Buy
- Analyst Count
- FNKO 4
- CRDF 5
- Target Price
- FNKO $7.13
- CRDF $11.10
- AVG Volume (30 Days)
- FNKO 783.3K
- CRDF 762.1K
- Earning Date
- FNKO 11-06-2025
- CRDF 10-29-2025
- Dividend Yield
- FNKO N/A
- CRDF N/A
- EPS Growth
- FNKO N/A
- CRDF N/A
- EPS
- FNKO N/A
- CRDF N/A
- Revenue
- FNKO $970,702,000.00
- CRDF $545,000.00
- Revenue This Year
- FNKO N/A
- CRDF N/A
- Revenue Next Year
- FNKO $10.57
- CRDF N/A
- P/E Ratio
- FNKO N/A
- CRDF N/A
- Revenue Growth
- FNKO N/A
- CRDF N/A
- 52 Week Low
- FNKO $2.22
- CRDF $1.90
- 52 Week High
- FNKO $14.65
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- FNKO 45.44
- CRDF 49.60
- Support Level
- FNKO $2.93
- CRDF $2.20
- Resistance Level
- FNKO $3.18
- CRDF $2.36
- Average True Range (ATR)
- FNKO 0.16
- CRDF 0.10
- MACD
- FNKO 0.01
- CRDF -0.00
- Stochastic Oscillator
- FNKO 36.19
- CRDF 51.77
About FNKO Funko Inc.
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.